Inviga Healthcare Fund has acquired a 21% stake in Forus Health Private Limited from TPG NewQuest by way of a secondary transaction, allowing TPG to exit from Forus.
JSA Advocates & Solicitors advised Forus Health and its Co-founder & CEO on this transaction.
The transaction team consisted of Manuel Jose (Partner) and Harshita Agarwal (Senior Associate).
Lex Consult represented TPG NewQuest on the transaction.
The transaction team consisted of Nidhi Khadria (Partner), Garima Agrawal (Senior Associate) and Tejas Kandalgaonkar (Associate).
Forus is a leading ophthalmic technology company renowned for its 3nethra series of eye screening devices that have screened over 22 million patients across 75 countries. Leveraging AI-driven diagnostics, its platform has served over 5 million patients worldwide, advancing early detection and accessibility in eye care. The company’s latest innovation, the 3nethra specto — a smartphone-controlled wearable digital refractor — is redefining tele-optometry and remote vision screening.
If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.